References in periodicals archive ?
Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St.
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study.
Factors associated with IQ scores in long-term survivors of childhood acute lymphoblastic leukemia.
Launched in the UK in August 2016, CALM is an open label, dose-escalation study designed to evaluate safety, tolerability and antileukemic activity of UCART19 in patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
Blinatumomab (MT103) is a next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of B-cell derived acute lymphoblastic leukemias and non-Hodgkin's lymphomas.
Healthcare company Pfizer Inc (NYSE:PFE) disclosed on Tuesday the submission of its Biologics License Application (BLA) for inotuzumab ozogamicin under Priority Review with the the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
European Hematology Association Annual Congress June 9 - 12, 2011, London, UK Abstract title: Clinical activity of the anti-CD19 BiTE blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL): Interim results of a phase 2 study Abstract number: 844 Presentation date and time: Saturday, June 11, 5:30 - 6:45 PM GMT First author: Max Topp, MD, University of Wuerzburg, Wuerzburg, Germany
M2 EQUITYBITES-February 22, 2017-Pfizer files inotuzumab ozogamicin with the US FDA for treating acute lymphoblastic leukemia
M2 PHARMA-October 20, 2015-Pfizer wins US FDA breakthrough therapy designation for ADC inotuzumab ozogamicin for acute lymphoblastic leukemia

Full browser ?